4-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patient
AASLD LiverLearning®. Wong V. Nov 14, 2016; 144752
Topic: Treatment and Clinical Trials
Dr. Vincent Wong
Dr. Vincent Wong
Login now to access Regular content available to all registered users.

AASLD Members enjoy free LiverLearning® Premium Access. Registrants of The Liver Meeting® receive LiverLearning® Premium Access for one year from the first day of the meeting.

You may also access AASLD content "anytime, anywhere" with the FREE AASLD LiverLearning® App for iOS and Android.

Abstract
Discussion Forum (0)
Rate & Comment (0)
ABSTRACT FINAL ID: 1860

TITLE: 4-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patient

SPONSORSHIP - THIS STUDY WAS SPONSORED BY: (IF THIS ABSTRACT WAS NOT SPONSORED PLEASE INDICATE):
The original trial was supported by Gilead Sciences, but the investigators have not received additional support for this follow-up study.

ABSTRACT BODY:
Background: With emerging efficacy and safety data, some patients with immune-tolerant chronic hepatitis B may receive temporary antiviral therapy (e.g. to prevent vertical transmission of hepatitis B virus [HBV]). The long-term outcome after cessation of antiviral therapy in such patients is unknown.
Methods: This was a follow-up study of a phase 2 trial at 2 Hong Kong centers (NCT00507507). Immune-tolerant patients were randomized to receive tenofovir disoproxil fumarate (TDF) or TDF plus emtricitabine (FTC) for 4 years. Patients who discontinued TDF±FTC were followed for another 4 years. Virological relapse was defined as HBV DNA >2000 IU/ml; clinical relapse was defined as HBV DNA >2000 IU/ml and alanine aminotransferase (ALT) >2 times the upper limit of normal (ULN).
Results: 20 patients stopped treatment (age 36±9; 65% females; 10 treated with TDF and 10 with TDF+FTC; 10 genotype B and 10 genotype C) and were followed for 206±14 weeks. All patients developed virological relapse at post-treatment Week 4 (HBV DNA 7.07±1.45 log IU/ml). 10 (50%) patients developed clinical relapse at 15±11 weeks, among whom 6 had ALT >5 times ULN and 3 had ALT >10 times ULN (highest 1149 U/l). All patients with clinical relapse had the first ALT elevation at or before Week 24. No patient developed liver decompensation or hepatocellular carcinoma. 11 (55%) patients were restarted on antiviral therapy (7 on entecavir and 4 on TDF); 4 achieved complete HBV DNA suppression, 10 had ALT normalization, and 1 achieved hepatitis B e antigen (HBeAg) seroconversion. Among the 9 patients not restarted on therapy, 2 patients had HBeAg seroconversion at week 45 and month 33, with normal ALT and HBV DNA of 7.12 log IU/ml and 1.62 IU/ml, respectively. The remaining 7 untreated patients continued to have positive HBeAg, high HBV DNA (8.50±0.34 log IU/ml) and normal ALT for 196±18 weeks post-treatment.
Conclusions: Rapid virological relapse is universal and clinical relapse is common after stopping antiviral therapy in patients with immune-tolerant chronic hepatitis B. Treatment initiation and cessation do not enhance HBeAg seroconversion. Therefore, immune-tolerant patients should only be treated when there are strong indications. If temporary antiviral therapy is needed, a drug with high genetic barrier to resistance should be used, and liver biochemistry should be monitored closely for at least 6 months after treatment cessation.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings